Last reviewed · How we verify

Agrylin (ANAGRELIDE)

Takeda · FDA-approved approved Small molecule Verified Quality 80/100

Agrylin works by inhibiting an enzyme that regulates platelet production, leading to a decrease in platelet count.

Agrylin (ANAGRELIDE) is a small molecule drug developed by SHIRE LLC and currently owned by Takeda Pharms Usa. It targets cGMP-inhibited 3',5'-cyclic phosphodiesterase A to reduce platelet count. Agrylin is a platelet-reducing agent approved by the FDA in 1997 for the treatment of essential thrombocythemia and thrombocytosis in myeloproliferative disease. The drug is now off-patent with multiple generic manufacturers available. Key safety considerations include monitoring for potential side effects such as diarrhea, dizziness, and fatigue.

At a glance

Generic nameANAGRELIDE
SponsorTakeda
Drug classPlatelet-reducing Agent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase A
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved
First approval1997

Mechanism of action

The precise mechanism by which anagrelide reduces blood platelet count is unknown. In cell culture studies, anagrelide suppressed expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: